Wayne Brisbane, MD
Urology · Los Angeles, CANPI 1346583176
Payments from drug & device makers
Across 105 payments — averaging $710.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EDAP Technomed Inc$48K
- Angiodynamics, Inc.$14K
- Blue Earth Diagnostics$5K
- Intuitive Surgical$5K
- Pfizer$327
- Astellas Pharma US Inc$228
- plus $388 from 7 others
What the payments were for
- Consulting fees$57,30982%
- Travel & lodging$1,9233%
- Food & beverage$5,8048%
- Education$4,5006%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EDAP Technomed Inc | 51 | $48,241 |
| Angiodynamics, Inc. | 18 | $14,452 |
| Blue Earth Diagnostics | 6 | $5,500 |
| Intuitive Surgical | 14 | $5,467 |
| Pfizer | 4 | $327 |
| Astellas Pharma US Inc | 2 | $228 |
| Smith+Nephew | 1 | $103 |
| Histosonics, Inc. | 1 | $97 |
| C. R. Bard, Inc. & Subsidiaries | 3 | $57 |
| AstraZeneca | 2 | $50 |
| AbbVie | 1 | $35 |
| Boston Scientific | 1 | $31 |
| Profound Medical Corp. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FOCAL ONE$14,830
- Nanoknife$14,190
- DA VINCI SP$4,500
- Da Vinci Surgical System$866
- XTANDI$498
- POSLUMA$296
- TALZENNA$271
- ORGOVYX$271
- STRAVIX PL$103
How this compares
$74,602 in reported general payments places this provider in the 90th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 30 | $81,438 |
| Silodosin | 12 | $1,355 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 40 | $958 |
| Tamsulosin Hcl | 42 | $439 |
| Finasteride | 27 | $329 |
| Bicalutamide | 14 | $269 |
| Oxybutynin Chloride ErOxybutynin Chloride | 13 | $148 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 25 | $59 |
Paid to pharmacies, not to this prescriber.
Other urology in Los Angeles
- Karim ChamieLos Angeles$4.3M
- Siamak DaneshmandLos Angeles$3.5M
- Arnold ChinLos Angeles$3.5M
- John KowalczykLos Angeles$1.8M
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.7M
- Brian ShuchLos Angeles$1.5M
- David JosephsonLos Angeles$1.5M
- Saum GhodoussipourLos Angeles$1.1M
- Stuart HoldenLos Angeles$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.